Oasmia is admitted to trading on NASDAQ OMX Stockholm
NASDAQ OMX Stockholm's Listing Committee has approved Oasmia Pharmaceutical AB
(”Oasmia” or the”Company”) for listing on NASDAQ OMX Stockholm's Small Cap
list. The first day of trading on NASDAQ OMX Stockholm will be 24 June 2010 and
the last day of trading on NGM Equity will be 23 June 2010.
The share will be traded under the same ticker symbol, OASM, ISIN SE0000722365.
No new shares will be issued in conjunction with the listing.
- It is very gratifying that Oasmia has been admitted to trading on NASDAQ OMX
Stockholm. We assess that NASDAQ OMX Stockholm is a more appropriate market
place for the Company's share and regards the list change as a natural step in
the Company's development. The admission to trading is a recognition of
Oasmia's high standards which facilitate a broadening of the ownership base and
improved liquidity in the share. We expect that the list exchange, through
increased interest in the Company from the equity market, customers, partners
and other interested parties will be beneficial for the Company's continued
development says Oasmia's CEO Julian Aleksov.
Oasmia has, in conjunction with the application for admission to trading,
prepared a Swedish prospectus which is available on the Company's website,
www.oasmia.se. The prospectus contains, among other things, information, which
has not been previously announced, in relation to the Company's planned
investments in tangible fixed assets as well as details about license and
distribution agreements. A number of risk factors, which may affect the
Company's development, are also presented in the prospectus. Potential
investors should consider these risk factors as well as all other information
contained in the prospectus.
About Oasmia
Oasmia Pharmaceutical AB develops second and third generation cancer drugs
based on nanotechnology for human and veterinary use. The broad portfolio is
focused on oncology and contains several promising products in clinical and
pre-clinical phase. Oasmia cooperates with leading universities and other
biotech companies to discover and optimize substances with a favorable safety
profile and better efficacy. The company name was registered in 1999 and is
based in Uppsala, Sweden.
Disclaimer
This press release includes forward-looking statements that involve a number of
risks and uncertainties, the outcome of which could materially and/or adversely
affect actual future results and the trading price of Oasmia's securities.
Specifically, the risks and uncertainties that could affect the development of
Paccal® Vet include risks associated with preclinical and clinical developments
in the biopharmaceutical industry in general, and with Paccal® Vet in
particular, including, without limitation, the potential for Paccal® Vet to be
proved safe and effective (or to achieve response rates) for the treatment of
the indications noted in this press release or any other indication,
determinations by regulatory, patent and administrative governmental
authorities, the potential that Paccal® Vet will not produce high rates of
complete remission in patients with mastocytoma, the possibility that the
registration trial for Paccal® Vet as a treatment for mastocytoma in dogs will
not occur, the possibility that the U.S. Food and Drug Administration will not
approve a phase III registration strategy for Paccal® Vet if proposed by
Oasmia, the potential that Abbott will not exercise its distribution rights,
Oasmia's ability to continue to raise capital as needed to fund its operations,
competitive factors, technological developments, and costs of developing,
producing and supplying Paccal® Vet. Except as may be required by law, Oasmia
does not intend to update or alter its forward-looking statements whether as a
result of new information, future events or otherwise.
For more information, please contact: Maria Lundén, Head of Public Relations,
Oasmia Pharmaceutical AB. E-mail: press@oasmia.com Phone: +46 (0) 18 50 54 40.
Information is also available at www.ngm.se and www.oasmia.com
